You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDifluprednate
Accession NumberDB06781
TypeSmall Molecule
GroupsApproved
DescriptionDifluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.
Structure
Thumb
Synonyms
DFBA
Difluoroprednisolone butyrate acetate
Durezol
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Durezolemulsion.5 mg/mLophthalmicAlcon Laboratories, Inc.2011-01-25Not applicableUs
Durezolemulsion.5 mg/mLophthalmicPhysicians Total Care, Inc.2011-08-29Not applicableUs
Durezolemulsion0.05 %ophthalmicAlcon Canada Inc2014-02-19Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIS8A06QG2QE
CAS number23674-86-4
WeightAverage: 508.5515
Monoisotopic: 508.227259852
Chemical FormulaC27H34F2O7
InChI KeyInChIKey=WYQPLTPSGFELIB-JTQPXKBDSA-N
InChI
InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
IUPAC Name
(1R,2S,8S,10S,11S,14R,15S,17S)-14-[2-(acetyloxy)acetyl]-1,8-difluoro-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl butanoate
SMILES
[H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[[email protected]](O)[C@@]1(F)[C@@]2([H])C[[email protected]](F)C2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Acetate salt
  • Cyclic alcohol
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Carboxylic acid ester
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of inflammation and pain associated with ocular surgery.
PharmacodynamicsDifluprednate is a corticosteroid used as an anti-inflammatory steroidal drug used primarily in ocular surgery.
Mechanism of actionCorticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of infammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Related Articles
AbsorptionDifluprednate penetrates the corneal epithelium rapidly and effectively. Low systemic absorption.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Difluprednate is rapidly deacetylated in the aqueous humor to difluoroprednisolone butyrate (DFB), the drug’s active metabolite. Endogenous tissue esterases then metabolize DFB to the inert metabolite hydroxyfluoroprednisolone butyrate (HFB), which limits systemic exposure to the active compound.

SubstrateEnzymesProduct
Difluprednate
Not Available
difluoroprednisolone butyrateDetails
Difluprednate
Not Available
Hydroxyfluoroprednisolone butyrate (HFB)Details
Route of elimination78.5% of radioactivity was excreted aftert 24 hours, and 99.5% by 7 days after a single dose of labeled difluprednate instilled in the right eyes of pigmented rabbits.
Half lifeNot Available
ClearanceNot Available
ToxicityPreclinical pharmacokinetic and toxicity studies have established that difluprednate ophthalmic emulsion 0.05% given 4 times a day is not toxic to the eye.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9904
Blood Brain Barrier+0.9908
Caco-2 permeable+0.6127
P-glycoprotein substrateSubstrate0.7679
P-glycoprotein inhibitor IInhibitor0.6413
P-glycoprotein inhibitor IINon-inhibitor0.789
Renal organic cation transporterNon-inhibitor0.8044
CYP450 2C9 substrateNon-substrate0.8882
CYP450 2D6 substrateNon-substrate0.9152
CYP450 3A4 substrateSubstrate0.7641
CYP450 1A2 substrateNon-inhibitor0.9138
CYP450 2C9 inhibitorNon-inhibitor0.911
CYP450 2D6 inhibitorNon-inhibitor0.8162
CYP450 2C19 inhibitorNon-inhibitor0.94
CYP450 3A4 inhibitorNon-inhibitor0.7263
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9014
Ames testNon AMES toxic0.9326
CarcinogenicityNon-carcinogens0.9242
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1368 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9677
hERG inhibition (predictor II)Non-inhibitor0.5493
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Emulsionophthalmic.5 mg/mL
Emulsionophthalmic0.05 %
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6114319 Yes1999-11-182019-11-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191-194Ercoli, A. and Gardi, R.; U.S. Patent 3,780,177; December 18,1973; assigned to Warner-Lambert Co.
Predicted Properties
PropertyValueSource
Water Solubility0.0097 mg/mLALOGPS
logP3.28ALOGPS
logP3ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)13.55ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area106.97 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity125.38 m3·mol-1ChemAxon
Polarizability51.46 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Ercoli, A. and Gardi, R.; U.S. Patent 3,780,177; December 18,1973; assigned to Warner-Lambert Co.

General References
  1. Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS: Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009 Jan;35(1):26-34. doi: 10.1016/j.jcrs.2008.09.024. [PubMed:19101421 ]
  2. Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29. [PubMed:19668594 ]
  3. Morton KD, Van de Kar LD, Brownfield MS, Bethea CL: Neuronal cell bodies in the hypothalamic paraventricular nucleus mediate stress-induced renin and corticosterone secretion. Neuroendocrinology. 1989 Jul;50(1):73-80. [PubMed:2666872 ]
External Links
ATC CodesD07AC19
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (149 KB)
MSDSDownload (129 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Difluprednate is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Difluprednate.
AldesleukinDifluprednate may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Difluprednate can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Difluprednate can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Difluprednate is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Difluprednate.
AmiodaroneThe serum concentration of Difluprednate can be increased when it is combined with Amiodarone.
Amphotericin BDifluprednate may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Difluprednate can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Difluprednate can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Difluprednate.
BazedoxifeneThe serum concentration of Difluprednate can be increased when it is combined with Bazedoxifene.
BendroflumethiazideDifluprednate may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Difluprednate.
Bismuth SubcitrateThe bioavailability of Difluprednate can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Difluprednate can be increased when it is combined with Boceprevir.
BumetanideDifluprednate may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Difluprednate.
Calcium carbonateThe bioavailability of Difluprednate can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Difluprednate can be decreased when it is combined with Carbamazepine.
CeritinibDifluprednate may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Difluprednate can be increased when it is combined with Ceritinib.
ChlorothiazideDifluprednate may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Difluprednate can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneDifluprednate may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Difluprednate can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Difluprednate can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Difluprednate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Difluprednate can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Difluprednate.
CoumaphosThe risk or severity of adverse effects can be increased when Difluprednate is combined with Coumaphos.
DarunavirThe serum concentration of Difluprednate can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Difluprednate is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Difluprednate is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Difluprednate is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Difluprednate is combined with Dichlorvos.
DienestrolThe serum concentration of Difluprednate can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Difluprednate can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Difluprednate.
DihydrotestosteroneDifluprednate may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Difluprednate is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Difluprednate is combined with Edrophonium.
EnzalutamideThe serum concentration of Difluprednate can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Difluprednate can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Difluprednate can be increased when it is combined with Estriol.
EstroneThe serum concentration of Difluprednate can be increased when it is combined with Estrone.
Etacrynic acidDifluprednate may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Difluprednate can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Difluprednate is combined with Fenthion.
FluoxymesteroneDifluprednate may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Difluprednate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Difluprednate can be decreased when it is combined with Fosphenytoin.
FurosemideDifluprednate may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Difluprednate is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Difluprednate can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Difluprednate is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Difluprednate.
HexestrolThe serum concentration of Difluprednate can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Difluprednate is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Difluprednate.
HydrochlorothiazideDifluprednate may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideDifluprednate may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Difluprednate can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Difluprednate.
IndapamideDifluprednate may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Difluprednate can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Difluprednate.
ItraconazoleThe serum concentration of Difluprednate can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Difluprednate can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Difluprednate can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Difluprednate can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Difluprednate can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Difluprednate can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Difluprednate can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Difluprednate can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Difluprednate is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Difluprednate.
MestranolThe serum concentration of Difluprednate can be increased when it is combined with Mestranol.
MethyclothiazideDifluprednate may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneDifluprednate may increase the fluid retaining activities of Methyltestosterone.
MetolazoneDifluprednate may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Difluprednate can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Minaprine.
MitotaneThe serum concentration of Difluprednate can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Difluprednate.
NefazodoneThe serum concentration of Difluprednate can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Difluprednate can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Neostigmine.
NevirapineThe serum concentration of Difluprednate can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Difluprednate is combined with Nicorandil.
OxandroloneDifluprednate may increase the fluid retaining activities of Oxandrolone.
OxymetholoneDifluprednate may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Difluprednate can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Difluprednate can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Difluprednate.
PhenytoinThe serum concentration of Difluprednate can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Physostigmine.
PiretanideDifluprednate may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Difluprednate can be increased when it is combined with Polyestradiol phosphate.
PolythiazideDifluprednate may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Difluprednate can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Difluprednate can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Pyridostigmine.
QuinestrolThe serum concentration of Difluprednate can be increased when it is combined with Quinestrol.
QuinethazoneDifluprednate may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Difluprednate.
RifabutinThe serum concentration of Difluprednate can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Difluprednate can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Difluprednate can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Difluprednate can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Difluprednate.
SaquinavirThe serum concentration of Difluprednate can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Difluprednate.
StanozololDifluprednate may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Difluprednate can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Difluprednate can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Difluprednate.
TelaprevirThe serum concentration of Difluprednate can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Difluprednate can be increased when it is combined with Telithromycin.
TestosteroneDifluprednate may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Difluprednate can be increased when it is combined with Tibolone.
TorasemideDifluprednate may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Difluprednate is combined with Trichlorfon.
TrichlormethiazideDifluprednate may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Difluprednate is combined with Tubocurarine.
VoriconazoleThe serum concentration of Difluprednate can be increased when it is combined with Voriconazole.
WarfarinDifluprednate may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Difluprednate can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Jamal KN, Callanan DG: The role of difluprednate ophthalmic emulsion in clinical practice. Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29. [PubMed:19668594 ]
  2. Tajika T, Takahashi H, Sakai Y, Fujii H, Isowaki A, Sakaki H: Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednate ophthalmic emulsion. Xenobiotica. 2010 Aug;40(8):569-77. doi: 10.3109/00498254.2010.490308. [PubMed:20509750 ]
Comments
comments powered by Disqus
Drug created on September 14, 2010 10:21 / Updated on September 29, 2016 03:39